Methods of treating a subject for a condition

• US 20060034847A1
• Filed: 08/11/2004
• Published: 02/16/2006
• Est. Priority Date: 08/11/2004
• Status: Active Grant

• Current Assignee: Palo Alto Investors
• Original Assignee: Palo Alto Investors
• Inventors: Lee, Patrick Yuarn-Bor, Yun, Anthony Joonkyoo
• Granted Patent: US 8,569,277 B2
• Time in Patent Office: Days
• US Class Current: 424/146.100
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/482 Serine endopeptidases (3.4.21)
• CPC Class Codes: A61K 38/49 Urokinase; Tissue plasminogen activator
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.

Claims

1. A method of simultaneously treating a subject for a blood clotting condition, autonomic dysfunction and an inflammatory condition, said method comprising:

(a) identifying said blood clotting condition, autonomic dysfunction and inflammatory condition in said subject; and

(b) administering an effective amount of a single pharmacological agent to said subject to simultaneously treat said subject for said blood clotting condition, autonomic dysfunction and inflammatory condition.

2. The method of claim 1, wherein said pharmacological agent is chosen from the group of:

an anti-inflammatory agent, anti-blood clotting agent and an autonomic nervous system modulator.

3. The method of claim 2, wherein said pharmacological agent is an anti-inflammatory agent.

4. The method of claim 3, wherein said anti-inflammatory agent is chosen from the group of:

steroids;

non steroidal anti-inflammatory agents;

glucocoricoid receptor blockers;

immunomodulators;

immunoregulatory antibodies that bind to an antigen;

immunoregulatory antibodies that react with an antibody;

dehydroepiandrosterones; and

antihistamines.

5. The method of claim 2, wherein said pharmacological agent is an anti-blood clotting agent.

6. The method of claim 5, wherein said anti-blood clotting agent is chosen from the group of:

triclopidone, clopidogrel, GP IIb/IIIa receptor antagonists, acetylsalicylic acid;

ximelagatran;

hirulog;

abciximab;

dipridamole;

anagrilide;

clopiogrel;

dipridamole;

eptifabatide;

ticlopidine;

tirofibam;

ardeparin;

dalteparin;

dnaparoid;

enoxaparin;

lepiudin;

heparin;

warfarin;

alteplase;

reteplase;

streptokinase;

urokinase;

aminocaproic acid; and

cilostazol; and

pentoxifylline.

7. The method of claim 2, wherein said pharmacological agent is an autonomic nervous system modulator.

8. The method of claim 7, wherein said autonomic nervous system modulator is an anti-adrenergic agent.

9. The method of claim 8, wherein said anti-adrenergic agent is chosen from the group of beta-blockers;

aldosterone antagonists;

angiotensin II receptor blockades;

angiotensin converting enzyme (“

ACE”

) inhibitors;

sympathomimetics;

calcium channel blockers;

sodium channel blockers;

vasopressin inhibitors;

peripheral adrenergic inhibitors;

blood vessel dilators;

central agonists;

combined alpha and beta-blockers;

alpha blockers;

renin inhibitors;

oxytocin inhibitors, and botulisim toxin.

10. The method of claim 1, wherein said pharmacological agent is chosen from the group of:

adiponectins;

phenserines;

phosphodiesterase 4 inhibitors;

valproale;

glucagon;

glucagon-like peptide-1;

glucocorticoid receptor blockers;

nicotine;

potassium channel blockers;

combination diuretics;

potassium sparing diuretics;

nitrate compounds;

gonadotropin-releasing hormone analogues;

vesicular monoamine transport (VMAT) inhibitors;

statins;

cyclic nucleotide monophosphodiesterase (PDB) inhibitors;

alcohols;

relaxin;

estrogen;

estrogen analogues, estrogen metabolites;

melatonin;

triglyceride lowering agents;

niacin;

anti-diabetic agents;

cholinergics;

acetylcholinesteriase inhibitors;

muscarinics;

magnesium;

dipeptidyl peptidase TV inhibitors;

dhca;

hmg1 antagonists, leptin;

Galanin like peptide;

gonadotropin-releasing hormone inhibitors;

testosterone inhibitors; and

progestrone inhibitors.

11. The method of claim 1, wherein said blood Clotting condition is a cardiovascular condition.

12. The method of claim 11, wherein said cardiovascular conditions is chosen from the group of:

atherosclerosis;

coronary artery disease;

hypertension;

hyperlipidemia;

eclampsia;

pre-eclampsia;

cardiomyopathy;

volume retention;

congestive heart failure;

aortic dissection;

aortic aneurysm;

arterial aneurysm;

myocardial infarction;

ischemia;

sudden adult death syndrome;

acute coronary syndromes;

thromboembolic disease;

deep vein thrombosis;

coagulopathy;

disseminated intravascular coagulation;

mesenteric ischemia;

syncope;

venous thrombosis;

arterial thrombosis;

malignant hypertension;

primary pulmonary hypertension;

secondary pulmonary hypertension; and

raynaud'"'"'s

13. The method of claim 11, wherein said method comprises identifying said cardiovascular condition.

14. The method of claim 1, wherein said inflammatory condition is chosen from the group of:

neurodegenerative conditions;

neuroinflammatory conditions;

orthopedic inflammatory conditions;

lymphoproliferative conditions;

autoimmune conditions;

infectious diseases;

pulmonary conditions;

transplant-related conditions;

gastrointestinal conditions;

endocrine conditions;

genitourinary conditions;

skin conditions;

aging associated conditions, neurologic conditions;

pediatric conditions;

Th-2 dominant conditions;

conditions that cause hypoxia;

conditions that hypercarbia;

conditions that cause hypercapnia;

conditions that cause acidosis;

conditions that cause acidemia;

OB-GYN conditions;

peripartum conditions;

pregnancy related conditions;

post-operative recovery conditions;

post-procedural recovery conditions;

chronic pain, trauma;

hospitalization;

glaucoma;

male infertility;

disorders of thermoregulation;

respiratory sinus arrhythmia;

VQ mismatch; and

fibromyalgia.

15. The method of clam 1, wherein said condition of autonomic dysfunction is chosen from the group of:

reflex sympathetic dystrophy;

migraines;

bladder dysfunction;

hepatorenal syndrome;

pulmonary renal syndrome;

shy draggers;

multi-symptom atrophy;

cardiogenic pulmonary edema;

cerebral vascular vasospasm;

migranes;

pregnancy-related arrhythmias;

transplant-related tachycardia;

QT interval prolongation, arterial vasospasm;

fatal arrhythmias;

coronary vasospasm;

sick sinus syndrome;

bradycardia;

tachycardia;

arrhythmias, and paroxysmal supraventricular tachycardia.

16. A method of treating a subject for an inflammatory condition, said method comprising:

(a) identifying said inflammatory condition; and

(b) administering an effective amount of at least one of an anti-blood clotting agent and an autonomic nervous system modulator to said subject to treat said subject for said inflammatory condition.

17-35. -35. (canceled)

36. A method of treating a subject for a blood clotting condition, said method comprising:

(a) identifying said blood clotting condition;

(b) administering an effective amount of at least one of an anti-inflammatory agent and an autonomic nervous system modulator to said subject to treat said subject for said blood clotting condition.

37-55. -55. (canceled)

56. A method of treating a subject for autonomic dysfunction said method comprising:

(a) identifying said autonomic dysfunction; and

(b) administering an effective amount of at least one of an anti-inflammatory agent and an anti-blood clotting agent to said subject to treat said subject for said autonomic dysfunction.

57-87. -87. (canceled)